drugset
drugset / Trial / NCT01444677

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

NCT01444677 ↗

Phase 1 Completed 40 enrolled Yungjin Pharm. Co., Ltd. KT&G Corporation · collab
RandomizedParallel-groupQuadruple-blindScreening

Summary

The purpose of this study is to investigate the safety and tolerability of MB12066 after a single or multiple oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single or multiple oral dose.

Timeline

Start
2011-04
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator LAPACHONE Small molecule 100 mg Oral
Comparator LAPACHONE Small molecule 200 mg Oral
Comparator LAPACHONE Small molecule 300 mg Oral
Comparator LAPACHONE Small molecule 400 mg Oral

Indications

metabolic syndrome X obesity disorder